A Clinical Research Study Designed To Determine If Treatment of Hepatitis C With Milk Thistle is More Effective Than No Treatment In Patients Infected With Both HIV And Hepatitis C

Henry Sacks

Status and phase

Completed

Phase 2

Phase 1

Conditions

Hepatitis C

HIV Infections

Treatments

Drug: Placebo

Drug: Silymarin

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00246363

GCO 02-1185

R21NR008860 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

There is some information available that indicates that Milk Thistle is an effective treatment for liver disease. This study will compare Milk Thistle with a placebo, (a medicine that looks just like Milk Thistle but does not contain any Milk Thistle) to see if people with both Hepatitis C and HIV infections show improvement or cure of Hepatitis C. The study will last one year.

Full description

Patients with many different diseases are requesting information from health care providers, (physicians and nurses) about alternative therapies. The paucity of evidence based information requires that rigidly structured clinical trials comparing dietary supplements, herbal products and other alternative modalities with either placebo or standard of care be conducted in a timely fashion. There is a body of evidence that Silymarin is both well tolerated and efficacious for the treatment of Hepatitis C. In patients co-infected with HIV & HCV, treatment choices are sometimes limited by intolerable toxicities of standard therapies for the treatment of HCV when combined with antiretroviral therapy for treatment of HIV. This study will seek to determine if Silymarin, an herbal product that is widely used, will be well tolerated and effective in slowing progression of liver damage in patients co-infected with HIV & HCV.

The Informed Consent Document contains all the required elements of informed consent as required by 21CFR50. The consent clearly states that this is research, participation is voluntary and that treatment with Silymarin may not be effective. Every effort has been made to outline whatever is known about any side effects. There are very few. All study participants are followed closely, are given their test results which are also shared with primary care providers. The investigators have convened a Data and Safety Monitoring Board and the Mount Sinai IRB has approved and will monitor the study.

Enrollment

40 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men and women 18 years old and older
Blood tests that are positive for a certain type of Hepatitis C known as
HIV +
Blood tests for liver function that indicate that the liver is working - must be obtained within one month of study entry
CD4 counts and HIV viral loads obtained within one month of study entry
(CD4 count <100 - eligible if HIV Viral Load <25,000)
(CD4 >100 - eligible with any HIV Viral Load)

Exclusion criteria

Women who are pregnant & breast-feeding & male partners of pregnant women
Diagnosis of advanced liver disease
Chronic liver disease other than Hepatitis C
HIV related infection within two weeks of study entry
Having had any organ transplant in the past including bone marrow
History of mental illness including depression within three months of study entry and attempted suicide or hospitalization for the treatment of mental illness at any time in the past
Chemotherapy treatment or treatment with steroids or other drugs that affect the immune system within six months of study entry
Problems with alcohol of illegal drugs within one year of study entry. Patients on methadone will be allowed to enter the study.